D
David Habart
Researcher at Scripps Research Institute
Publications - 32
Citations - 1773
David Habart is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Von Willebrand disease & Transplantation. The author has an hindex of 13, co-authored 30 publications receiving 1666 citations.
Papers
More filters
Journal ArticleDOI
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)
Alberto Tosetto,Francesco Rodeghiero,Giancarlo Castaman,Anne Goodeve,Augusto B. Federici,Javier Batlle,Dominique Meyer,Edith Fressinaud,Claudine Mazurier,Jenny Goudemand,Jeroen Eikenboom,Reinhard Schneppenheim,U. Budde,Jørgen Ingerslev,Zdena Vorlova,David Habart,Lars Holmberg,Stefan Lethagen,John Pasi,Frank Hill,Ian R. Peake +20 more
TL;DR: Higher BS was related with increasing likelihood of VWD, and a mucocutaneous BS was strongly associated with bleeding after surgery or tooth extraction, which is potentially useful for a more accurate diagnosis of type 1 VWD.
Journal ArticleDOI
Phenotype and genotype of a cohort of families historically diagnosed with Type 1 von Willebrand Disease in the European study, molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand Disease (MCMDM-1VWD)
Anne Goodeve,Jeroen Eikenboom,Giancarlo Castaman,Francesco Rodeghiero,Augusto B. Federici,Javier Batlle,Dominique Meyer,Claudine Mazurier,Jenny Goudemand,Reinhard Schneppenheim,Ulrich Budde,Jørgen Ingerslev,David Habart,Zdena Vorlova,Lars Holmberg,Stefan Lethagen,John Pasi,Frank Hill,Mohammad Hashemi Soteh,Luciano Baronciani,Christer Halldén,Andrea Guilliatt,Will Lester,Ian R. Peake +23 more
TL;DR: This study recruited families based on previous type 1 VWD diagnosis and stratified patients into those with or without phenotypes suggestive of qualitative VWF defects (abnormal multimers) and with or with mutations.
Journal ArticleDOI
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD) : results from the European Study MCMDM-1VWD
Giancarlo Castaman,Stefan Lethagen,Augusto B. Federici,Alberto Tosetto,Anne Goodeve,Ulrich Budde,Javier Batlle,Dominique Meyer,Claudine Mazurier,Edith Fressinaud,Jenny Goudemand,Jeroen Eikenboom,Reinhard Schneppenheim,Jørgen Ingerslev,Zdena Vorlova,David Habart,Lars Holmberg,John Pasi,Frank Hill,Ian R. Peake,Francesco Rodeghiero +20 more
TL;DR: Response to desmopressin in these VWD patients seemed to be associated with the location of the causative mutation, and the presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD.
Journal ArticleDOI
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)
U. Budde,Reinhard Schneppenheim,Jeroen Eikenboom,Anne Goodeve,K. Will,E. Drewke,Giancarlo Castaman,Francesco Rodeghiero,Augusto B. Federici,Javier Batlle,A Perez,Dominique Meyer,Claudine Mazurier,Jenny Goudemand,Jørgen Ingerslev,David Habart,Zdena Vorlova,Lars Holmberg,Stefan Lethagen,John Pasi,Frank Hill,Ian R. Peake +21 more
TL;DR: To evaluate the proportion of misclassification of patients historically diagnosed with type 1 VWD using detailed analysis of the VWF multimer structure, the finding that even slightly aberrant multimers are highly predictive for the presence of VWF mutations is supported.
Journal ArticleDOI
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Sandra L. Haberichter,Sandra L. Haberichter,Sandra L. Haberichter,Giancarlo Castaman,Ulrich Budde,Ian R. Peake,Anne Goodeve,Francesco Rodeghiero,Augusto B. Federici,Javier Batlle,Dominique Meyer,Claudine Mazurier,Jenny Goudemand,Jeroen Eikenboom,Reinhard Schneppenheim,Jørgen Ingerslev,Zdena Vorlova,David Habart,Lars Holmberg,Stefan Lethagen,John Pasi,Frank Hill,Robert R. Montgomery,Robert R. Montgomery,Robert R. Montgomery +24 more
TL;DR: Data indicate that a reduced VWF survival is found in a subpopulation of patients with type 1 VWD, and the systematic assay of both plasma VWF and the VWF propeptide in moderately severe type 2 VWD patients may identify patients with a reducedVWF survival phenotype.